Mounjaro Dosage Chart: Understanding Titration, Biomarkers, and Personalization

Last reviewed: May 17, 2026

Last updated: May 17, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Mounjaro dosage follows a standardized titration schedule beginning at 2.5 mg weekly, with 2.5 mg increments every four weeks until reaching a target maintenance dose, typically 5 mg or 10 mg depending on clinical goals. This stepwise approach allows providers to assess tolerability and individual response before advancing to higher doses.

For patients considering GLP-1 therapy, understanding dosage progression, individual variation in tolerability, and the role of biomarkers can support more informed conversations with healthcare providers. PlexusDx precision-wellness approach integrates genetic and metabolic context to help optimize therapy decisions alongside clinical dosing guidelines.

Standard Mounjaro Titration Protocol and Timeline

Mounjaro titration begins at 2.5 mg once weekly for the first four weeks. If tolerated, the dose advances to 5 mg weekly for weeks five through eight. Further escalation proceeds in 2.5 mg increments at four-week intervals, up to maximum doses of 10 mg or 15 mg weekly, depending on clinical indication and tolerability.

The structured four-week intervals allow time to assess gastrointestinal side effects, metabolic response, and individual tolerability before advancing. Clinical response varies; some patients reach therapeutic benefit at lower maintenance doses, while others require higher doses. Provider assessment determines optimal dosing for each individual.

Dosage Escalation Phases and Clinical Response Monitoring

Each dosage phase presents distinct considerations. Early phases (2.5–5 mg) establish baseline tolerability and initial glycemic or weight-reduction response. Mid-range phases (7.5 mg) represent therapeutic maintenance for many patients. Higher doses (10–15 mg) target more intensive metabolic or weight-reduction goals but carry increased risk of gastrointestinal side effects and nausea.

Dosage Phase	Weekly Dose	Typical Duration	Clinical Focus
Initiation	2.5 mg	4 weeks	Baseline tolerability assessment
Early escalation	5 mg	4 weeks	Initial therapeutic response
Mid-range maintenance	7.5 mg	4+ weeks	Common effective dose for many patients
Higher-intensity therapy	10–15 mg	4+ weeks	Intensified metabolic or weight-reduction goals

Tolerability Factors and Individual Response Variation

Gastrointestinal side effects—nausea, vomiting, constipation, and reduced appetite—affect tolerability during titration. These effects often diminish over time but may prompt dose adjustment or slowed escalation in some patients. Genetic and biomarker factors can influence how individuals metabolize and respond to GLP-1 agonists, contributing to variation in both tolerability and efficacy.

Dose adjustments may be necessary if side effects are severe or persistent. Some patients benefit from remaining at lower maintenance doses with good clinical outcomes, while others tolerate higher doses without significant discomfort. Regular provider communication during titration ensures safe, individualized progression.

Biomarker Context and Precision Therapy Considerations

Beyond standard dosage charts, biomarker and genetic data can provide additional context for personalizing GLP-1 therapy. Specific genetic variants in GLP-1 receptor pathways, appetite regulation, and lipid metabolism may correlate with individual tolerability and therapeutic response. This information should complement, not replace, clinical assessment and provider guidance.

PlexusDx Precision Peptide Genetic Test examines key variants in GLP-1 receptor signaling, GIPR pathways, and metabolism-related genes that may help contextualize individual predispositions in peptide therapy response. These insights can support more informed conversations with providers about dosing strategy, tolerability expectations, and therapy optimization without guaranteeing specific outcomes.

How PlexusDx Supports a More Personalized Approach

Genetic variants in GLP-1 receptor (rs6923761), GIPR (rs1800437), and metabolic genes like FTO and MC4R may provide context for individual variation in dosage tolerability and efficacy. This information may help provide context for personalized therapy decisions when interpreted with a qualified healthcare provider.

PlexusDx Precision Peptide Genetic Test reveals predispositions in peptide pathway genes relevant to GLP-1 agonist response. The test does not predict exact medication response or guarantee outcomes; rather, it identifies genetic factors that can support a more nuanced conversation between patient and provider about dosing expectations and tolerability planning.

Understanding your genetic profile in peptide metabolism and receptor signaling can empower collaborative discussions with your healthcare provider about optimal dosage strategy, expected side-effect patterns, and whether compounded GLP-1 options might align with your personalized therapy plan.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the starting dose of Mounjaro, and how quickly does it increase?

Mounjaro dosing begins at 2.5 mg once weekly. The dose increases by 2.5 mg increments every four weeks, provided tolerability is acceptable. Most patients reach maintenance doses of 5–10 mg within 8–12 weeks.

Can I stay on a lower Mounjaro dose if it works for me?

Yes. Some patients achieve therapeutic benefit at 5 mg or 7.5 mg weekly and do not require escalation to higher doses. Provider assessment determines whether your current dose aligns with your clinical goals and tolerability.

How do side effects influence dosage escalation?

Gastrointestinal side effects may prompt slowed escalation or dose adjustment. Providers monitor tolerability at each phase and may extend duration at current dose or reduce escalation pace if nausea, vomiting, or constipation is significant.

What are compounded GLP-1 alternatives if Mounjaro is unavailable or cost-prohibitive?

PlexusDx offers compounded semaglutide injection ($189/mo) and compounded tirzepatide injection ($289/mo) from licensed 503A pharmacies. Both follow similar titration protocols and may be more accessible than branded options.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

Genetic variants in GLP-1 receptor and metabolic pathways may provide context for individual predispositions; however, genetics does not guarantee specific tolerability or efficacy. PlexusDx Precision Peptide Genetic Test can support conversation with your provider about personalized dosing strategy.

Related Reading

• Hers Mounjaro
• Hims Mounjaro
• Mounjaro For Hypertension
• Mounjaro For Endometriosis

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.